GlassScriptPhysician profile
Christine Canterbury
NPI 1104899152
$7,681.36
in general payments reported to CMS, 2019-2025
24 companies · $231 in 2025
The $231 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $534 · 2020: $34.90 · 2021: $291 · 2022: $309 · 2023: $6,041 · 2024: $241 · 2025: $231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $4,668 · Travel and Lodging: $929 · Food and Beverage: $917.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $4,667.64 |
| Travel and Lodging | $928.70 |
| Food and Beverage | $917.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $5,965.98 | 2022-2025 | Davinci Xi, Da Vinci Surgical System |
| Coloplast Corp | $527.28 | 2019-2023 | Saffron |
| Galderma Laboratories, L.P. | $254.10 | 2021-2022 | |
| Astellas Pharma US INC | $210.55 | 2023-2024 | Veozah |
| Abbvie INC. | $123.12 | 2019-2023 | Lo Loestrin Fe |
| Biogen, INC. | $97.46 | 2025 | Zurzuvae |
| Allergan, INC. | $72.10 | 2019 | |
| Sage Therapeutics, LLC | $71.57 | 2024-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $60.73 | 2023-2024 | Gemtesa, Myfembree |
| Bayer Healthcare Pharmaceuticals INC. | $37.76 | 2019-2020 | |
| Conmed Corporation | $32.78 | 2023 | Airseal |
| Caldera Medical, INC | $31.85 | 2023 | Desara |
| Merck Sharp & Dohme LLC | $31.33 | 2021-2022 | |
| Boston Scientific Corporation | $29.11 | 2023 | Solyx Sis System |
| Coopersurgical, INC. | $27.05 | 2021-2024 | Paragard T 380a |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Myovant Sciences INC. | $26.69 | 2022 | |
| Duchesnay USA Incorporated | $18.54 | 2019 | |
| Exeltis, USA INC. | $15.90 | 2021 | |
| Shield Therapeutics INC | $14.47 | 2023 | Accrufer |
| Lupin INC. | $13.15 | 2019 | |
| Organon LLC | $10.64 | 2022 | |
| Aspira Women'S Health INC | $9.20 | 2024 | Ova1 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christine Canterbury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.